ERBB2 and breast carcinoma: The E75 (KIFGSLAFL; HER2, 369‒377) sequence derived from HER2 protein’s extracellular region has also been employed in the formulation of peptide-based cancer vaccine (nelipepimut-S) to prevent breast cancer recurrence in high-risk patients [28,29].